FDA DEVICE FACTS
ETEST Imipenem/Relebactam (IPR) (0.002/4-32/4 ug/mL)
Biomerieux S.A.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
ETEST® is a manual, quantitative technique for determination of antimicrobial susceptibility of non-fastidious Gram -negative and Gram -positive a erobic bacteria and fastidious bacteria. The system comprises a predefined antibiotic gradient which is used to determine the Minimum Inhibitory Concentration (MIC, in μg/mL) of different antimicrobial agents against microorganisms tested on agar media after overnight incubation. Imipenem/Relebactam has been shown to be active against the Gram -negative aerobic microorganisms listed below according to the FDA label for this antimicrobial agent. ETEST ® IPR can be used to determine the MIC of Imipenem/Relebactam against the following microorganisms: Active both in vitro and in clinical infections:
• Citrobacter freundii
• Enterobacter cloacae
• Escherichia coli
• Klebsiella aerogenes
• Klebsiella oxytoca
• Klebsiella pneumoniae
• Pseudomonas aeruginosa
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。